Get VENCLEXTA treatment support: (844) 926-6727, M–F, 7am–7pm CST | Sign up for THE VEN ZONE
Serious illnesses can come with many challenges. Getting VENCLEXTA, once it has been prescribed, shouldn’t be one of them.
There can be options that can help you afford your VENCLEXTA, no matter what type of health insurance you have.
Genentech Oncology Co-pay Assistance Program for VENCLEXTA
The Genentech Oncology Co-pay Assistance Program* for VENCLEXTA can help you with the out-of-pocket costs for your VENCLEXTA, GAZYVA® (obinutuzumab), or rituximab prescriptions, if you’re eligible.
You pay as little as $5 per prescription for VENCLEXTA + GAZYVA or VENCLEXTA + rituximab if you qualify for the Genentech Oncology Co-pay Assistance Program. The program covers the rest, up to a $25,000 per product limit per 12 months.
Terms and Conditions
*This Genentech Oncology Co-pay Assistance Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid, or any other federal or state government program to pay for their medications are not eligible.
Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all remaining out-of-pocket costs.
All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this program. The program is only valid in the United States and U.S. Territories. This program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The patient, guardian, prescriber, hospital and any other person using the program agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer of this program. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Additional terms and conditions apply. Please visit copayassistancenow.com for the full list of Terms and Conditions.
Find out if you’re eligible
Referrals to Independent Co-pay Assistance Foundations
An independent co-pay assistance foundation† is a charitable organization that gives financial assistance for medicines. Foundations help patients with public or commercial health insurance.
†Independent co-pay assistance foundations have their own rules for eligibility. Genentech has no involvement or influence in independent foundation decision-making or eligibility criteria and does not know if a foundation will be able to help you. We only can refer you to a foundation that supports your disease state. This information is provided as a resource for you. Genentech does not endorse or show preference for any particular foundation. The foundations in this list may not be the only ones that might be able to help you.
Find a list of independent co-pay assistance foundations
Actor portrayal.
Referrals to Independent Co-pay Assistance Foundations
An independent co-pay assistance foundation* is a charitable organization that gives financial assistance for medicines. Foundations help patients with public or commercial health insurance.
*Independent co-pay assistance foundations have their own rules for eligibility. Genentech has no involvement or influence in independent foundation decision-making or eligibility criteria and does not know if a foundation will be able to help you. We only can refer you to a foundation that supports your disease state. This information is provided as a resource for you. Genentech does not endorse or show preference for any particular foundation. The foundations in this list may not be the only ones that might be able to help you.
Find a list of independent co-pay assistance foundations
Genentech Patient Foundation
The Genentech Patient Foundation† gives free Genentech medicine to people who don’t have health insurance coverage or who have financial concerns and meet eligibility criteria.‡
Speak to a Foundation Specialist to see if you qualify
†If you have health insurance, you should try to get other types of financial assistance, if available. You also need to meet income requirements. If you do not have insurance, or if your insurance does not cover VENCLEXTA, you must meet a different set of income requirements.
‡Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.
Actor portrayal.
Monday-Friday, 7am-7pm CST
‡§The nurses from the nurse support line are provided by AbbVie and do not work under the direction of a healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.
VENCLEXTA is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
It is not known if VENCLEXTA is safe and effective in children.
VENCLEXTA can cause serious side effects, including:
Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS. You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do blood tests to check for TLS when you first start treatment and during treatment with VENCLEXTA. It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you have any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, or muscle or joint pain.
Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS. Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose, on the day of your first dose of VENCLEXTA, and each time your dose is increased.
Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you have side effects. When restarting VENCLEXTA after stopping for 1 week or longer, your healthcare provider may again check for your risk of TLS and change your dose.
Certain medicines must not be taken when you first start taking VENCLEXTA and while your dose is being slowly increased because of the risk of increased TLS.
Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:
You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit while you are taking VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.
VENCLEXTA can cause serious side effects, including:
Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with VENCLEXTA.
The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell counts; low platelet counts; low red blood cell counts; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet.
VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of VENCLEXTA. For more information, ask your healthcare provider or pharmacist.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088.
If you cannot afford your medication, contact genentech-access.com/patient/brands/venclexta for assistance.
US-VENC-210314
